Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer.
Aged
Antineoplastic Agents
/ therapeutic use
Biomarkers
/ metabolism
Chemotherapy, Adjuvant
Cystectomy
Female
Humans
Immunohistochemistry
Keratin-20
/ metabolism
Keratin-5
/ metabolism
Keratin-6
/ metabolism
Logistic Models
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Invasiveness
Proportional Hazards Models
Retrospective Studies
Survival Rate
Urinary Bladder Neoplasms
/ metabolism
Biomarker
Bladder cancer
Chemotherapy
Immunohistochemistry
Journal
Investigative and clinical urology
ISSN: 2466-054X
Titre abrégé: Investig Clin Urol
Pays: Korea (South)
ID NLM: 101674989
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
27
09
2020
revised:
23
12
2020
accepted:
31
12
2020
entrez:
4
5
2021
pubmed:
5
5
2021
medline:
9
2
2022
Statut:
ppublish
Résumé
A readily accessible biomarker to identify which patients with bladder cancer are more likely to respond to neoadjuvant chemotherapy (NAC) could help clinicians avoid unnecessary chemotherapy and prevent its subsequent complications in some patients. The primary objective of this study was to investigate the association of immunohistochemical markers of tumor subtype with response to NAC and survival of patients with muscle-invasive bladder cancer (MIBC). MIBC patients treated with NAC were retrospectively included. The tissue microarrays were assembled from transurethral resection of bladder tumor (TURBT) specimens and immunohistochemistry (IHC) was performed. The association of independent variables, including IHC markers, and clinical covariates with clinical complete response to NAC and with overall survival was assessed by using logistic regression and Cox proportional hazard regression analysis, respectively. Kaplan-Meier curves were plotted for different IHC-based tumor subtypes. Data from 140 MIBC patients treated with NAC were retrospectively reviewed. A total of 63 patients with available TURBT specimens were eligible to be included in the analysis. Our results showed that the IHC signature of KRT5/6(+)/KRT20(-), as a combined marker of basal subtype, was the only covariate significantly associated with complete response to NAC (p=0.037). Moreover, we found no statistically significant differences in overall survival between different IHC-based subtypes (p=0.721). The IHC expression of KRT5/6 and KRT20, as a readily accessible combined marker, may help us to identify the patients most likely to benefit from chemotherapy. The clinical utility of this marker needs to be established in larger prospective studies.
Identifiants
pubmed: 33943049
pii: 62.274
doi: 10.4111/icu.20200425
pmc: PMC8100015
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers
0
KRT20 protein, human
0
KRT5 protein, human
0
KRT6A protein, human
0
Keratin-20
0
Keratin-5
0
Keratin-6
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
274-281Informations de copyright
© The Korean Urological Association, 2021.
Déclaration de conflit d'intérêts
The authors have nothing to disclose.
Références
Front Oncol. 2020 Feb 07;10:102
pubmed: 32117752
J Pathol. 2017 May;242(1):113-125
pubmed: 28195647
Eur Urol. 2020 Apr;77(4):420-433
pubmed: 31563503
Nature. 2014 Mar 20;507(7492):315-22
pubmed: 24476821
Eur Urol. 2017 Oct;72(4):544-554
pubmed: 28390739
Eur Urol. 2019 Jan;75(1):18-22
pubmed: 30266310
EBioMedicine. 2016 Oct;12:105-117
pubmed: 27612592
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3110-5
pubmed: 24520177
N Engl J Med. 2003 Aug 28;349(9):859-66
pubmed: 12944571
World J Urol. 2019 Sep;37(9):1759-1765
pubmed: 30392011
J Clin Oncol. 2011 Jun 1;29(16):2171-7
pubmed: 21502557
Cancers (Basel). 2020 Jul 03;12(7):
pubmed: 32635360
Eur Urol. 2016 May;69(5):855-62
pubmed: 26343003
J Histochem Cytochem. 2013 Feb;61(2):116-24
pubmed: 23172795
J Vis Exp. 2012 May 31;(63):
pubmed: 22688270
Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1408-1416
pubmed: 29960059
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Methods Mol Biol. 2018;1655:53-64
pubmed: 28889377
Cancer Cell. 2014 Feb 10;25(2):152-65
pubmed: 24525232
Eur Urol. 2012 Jun;61(6):1229-38
pubmed: 22189383
Sci Rep. 2020 Jun 16;10(1):9743
pubmed: 32546765
Eur Urol. 2020 Jun;77(6):701-710
pubmed: 32165065
J Pathol. 2001 Jul;194(3):349-57
pubmed: 11439368